elaprase- idursulfase solution, concentrate
takeda pharmaceuticals america, inc. - idursulfase (unii: 5w8jgg2651) (idursulfase - unii:5w8jgg2651) - idursulfase 6 mg in 3 ml - elaprase is indicated for patients with hunter syndrome (mucopolysaccharidosis ii, mps ii). elaprase has been shown to improve walking capacity in patients 5 years and older. in patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with elaprase has reduced spleen volume similarly to that of adults and children 5 years of age and older. the safety and efficacy of elaprase have not been established in pediatric patients less than 16 months of age [see use in specific populations (8.4)]. none. risk summary there are no adequate and well-controlled studies with elaprase use in pregnant women. available data from a small number of postmarketing cases with elaprase use in pregnancy are insufficient to inform drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. in an animal reproduction study, no evidence of adverse effects on pre- and post-natal development wa
elaprase idursulfase-rhu concentrate for solution for iv infusion vial
sanofi-aventis australia pty ltd - idursulfase, quantity: 6 mg - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections; dibasic sodium phosphate heptahydrate; monobasic sodium phosphate monohydrate; polysorbate 20 - for the long term treatment of patients with hunter syndrome (mucopolysaccharidosis ii, mps ii) for the long term treatment of patients with hunter syndrome (mucoplysaccharidosis ii, mps ii).
elaprase
takeda israel ltd - idursulfase - concentrate for solution for infusion - idursulfase 2 mg/ml - idursulfase - idursulfase - long term treatment of patients with hunter syndrome (mps ii).
elaprase
takeda pharmaceuticals international ag ireland branch - idursulfase - mucopolysaccharidosis ii - other alimentary tract and metabolism products, - elaprase is indicated for the long-term treatment of patients with hunter syndrome (mucopolysaccharidosis ii, mps ii). heterozygous females were not studied in the clinical trials.
elaprase (tm) solution for intravenous infusion 2mg ml
sanofi-aventis singapore pte. ltd. - idursulfase - infusion, solution concentrate - 6.0 mg/vial - idursulfase 6.0 mg/vial
elaprase 6mg3ml concentrate for solution for infusion vials
shire pharmaceuticals ltd - idursulfase - solution for infusion - 2mg/1ml
elaprase
pharmacy retailing (nz) ltd t/a healthcare logistics - idursulfase 2 mg/ml; - concentrate for infusion - 2 mg/ml - active: idursulfase 2 mg/ml excipient: dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 20 sodium chloride water for injection - elaprase is indicated for the long term treatment of patients with hunter syndrome (mucopolysaccharidosis ii, mps ii).
elaprase solution
takeda canada inc - idursulfase - solution - 2mg - idursulfase 2mg - enzymes
elaprase
genzyme australasia pty ltd - idursulfase -
elaprase 2 mg/ ml solución para infusión i.v.
shire human genetic therapies inc. - idursulfasa - idursulfasa....2 mg